(PEG)-BHD1028, a novel peptide agonist to adiponectin receptors, AdipoR1 and R2, was evaluated as a potential therapeutic agent for treating dry eye disease (DED) in experimentally induced dry eye (EDE) animal models based on the reported biological functions of globular adiponectin and the abundance of adiponectin receptors in both anterior and posterior portions of the eye [6,29]. The gene discussed is ADIPOQ; the disease is Keratoconjunctivitis sicca.